ithium effect on Brain derived neurotrophic factor in ischemic stroke
- Conditions
- Ischemic stroke.Cerebral infarction
- Registration Number
- IRCT2013110515290N1
- Lead Sponsor
- Vice chancellor for research, Ahvaz Jundishapur University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
1-age: 50-90. 2-Ischemic stroke including subtypes 1, 4, 5 of TOAST classification system (all types of ischemic stroke except cardioembolic types). 3-maximum time after stroke is not over than 48hours. 4-no participation in any another clinical trial
Exclusion criteria: 1-Any type of intracranial or subarachnoid hemorrhage or hemorrhagic transformation in admission period 2-Any organ damage that interact with lithium prescription: acute or chronic renal failure(Creatinine more than 1.2), CHF(Ejection Fraction lesser than 40% or History of orthopnea or Paroxysmal nocturnal dyspnea), recent Myocardial Infarction(current 3 months), pulmonary edema, respiratory distress, history of any thyroid dysfunction,acute or chronic diarrhea with severe dehydration or blood urea nitrogen -serum creatinine ratio more than 20. 3-Any drug consumption that interact with lithium prescription(thiazides, Angiotensin converting enzyme(ACE) inhibitors, angiotensin receptor blockers except losartane, Calcium channel blockers, forusemide more than 80mg,NSAIDs except aspirin.4 -Pregnancy or lactation period in nonmenopausal females
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method BDNF serum level. Timepoint: 5 and 30 days after lithium carbonate prescription. Method of measurement: ELISA-BOSTER company kit-pico gram per deciliter.
- Secondary Outcome Measures
Name Time Method Mortality rate in intervention and control groups. Timepoint: the day 15 and 30 after lithium or placebo administration. Method of measurement: members counting.